Actively Recruiting
Endometriosis and Microvascular Dysfunction: Role of Inflammation
Led by Penn State University · Updated on 2024-11-05
24
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to better understand the underlying mechanisms associated with elevated cardiovascular disease risk in women with endometriosis, and to measure the effectiveness of emerging endometriosis treatments on outcomes specific to cardiovascular dysfunction. Epidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk. Circulating factors, low-density lipoprotein (LDL) and oxidized LDL (oxLDL), are two of many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 signal transduction functionally results in pronounced endothelial dysfunction, a hallmark of CV. The investigators hypothesis that one factor mediating the elevated risk of cardiovascular disease in endometriosis is systemic inflammation and activation of LOX-1 receptor mechanisms.
CONDITIONS
Official Title
Endometriosis and Microvascular Dysfunction: Role of Inflammation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy women aged 18 to 45 years with regular menstrual cycles or using oral contraceptives
- Women aged 18 to 45 years diagnosed with endometriosis by laparoscopy within the past 5 years
- Use of Tylenol allowed for acute pain
- Use of contraceptives allowed
You will not qualify if you...
- Use of nicotine-containing products such as smoking or chewing tobacco
- Diabetes with HbA1C of 6.5% or higher
- Blood pressure higher than 140/90
- Taking medications that affect peripheral vascular control (e.g., insulin sensitizers, cardiovascular drugs)
- Pregnant or breastfeeding
- Use of illicit or recreational drugs
- Abnormal liver function or persistent unexplained high liver enzymes
- Skin diseases, rashes, pigmentation disorders, or known skin allergies
- Diagnosed or suspected metabolic or cardiovascular diseases
- Known allergy to latex or study substances including salsalate or simvastatin
- History of gastrointestinal bleeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Pennsylvania State University
University Park, Pennsylvania, United States, 16801
Actively Recruiting
Research Team
L
Lacy M Alexander, Ph.D.
CONTACT
S
Susan Slimak, RN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here